SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2011 / Cilt: 11 - Sayı: 7

Yeni başlayan atriyal fibrilasyonun ilaçla sinüs ritmine döndürülmesi: Üç antiaritmik ilaçla gerçekleştirilen randomize, plasebo-kontrollü çalışma

Pharmacological conversion of recent atrial fibrillation: A randomized, placebo-controlled study of three antiarrhythmic drugs

Anesti KONDILI
İdriz BALLA
Elizana PETRELA
Pages
600–606
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The primary end-point was achieved in 87.5% of patients with flecainide, 85% of patients with amiodarone, 85% of patients with propafenone and 17.5% of patients with placebo (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we randomly compared single oral doses of flecainide, amiodarone and propafenone versus placebo for the conversion of recent atrial fibrillation (AF) (within 48 hours).
📊
Key Findings & Data:Methods: This is a randomized prospective, placebo-controlled single-blind study that included 160 consecutive patients with recent AF who were randomly assigned to single oral doses of flecainide (3 mg/kg of weight, n=40), amiodarone (30 mg/kg weight, n=40), propafenone (8.5 mg/ kg of weight, n=40) or placebo (n=40).
💡
Conclusion & Impact:Results: The primary end-point was achieved in 87.5% of patients with flecainide, 85% of patients with amiodarone, 85% of patients with propafenone and 17.5% of patients with placebo (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we randomly compared single oral doses of flecainide, amiodarone and propafenone versus placebo for the conversion of recent atrial fibrillation (AF) (within 48 hours). Methods: This is a randomized prospective, placebo-controlled single-blind study that included 160 consecutive patients with recent AF who were randomly assigned to single oral doses of flecainide (3 mg/kg of weight, n=40), amiodarone (30 mg/kg weight, n=40), propafenone (8.5 mg/ kg of weight, n=40) or placebo (n=40). The primary end-point was conversion rate at 24 hours after the drug intake. The association between antiarrhythmic use and conversion rate was tested with multiple logistic regressions. Results: The primary end-point was achieved in 87.5% of patients with flecainide, 85% of patients with amiodarone, 85% of patients with propafenone and 17.5% of patients with placebo (p

Özet

Amaç: Atriyal fibrilasyonun (AF) sinüs ritmine döndürülmesi çoğu kez emboli riskini ve hemodinamik bozulmanın azaltılması için yapılır. Bu çalışmada, son 48 saat içinde AF geçirmiş hastalar üzerinde tek oral doz flekainid, amiyodaron ve propafenon ile atriyal fibrilasyonun sinüs ritmine dönüşümü üzerindeki etkileri plasebo ile randomize olarak karşılaştırılmıştır. Yöntemler: Bu çalışma 160 hasta üzerinde yapılmış, hastalara rastgele olmak üzere flekainid (3 mg/kg, n=40), amiyodaron (30 mg/kg, n=40), propafenon (8.5 mg/kg, n=40) veya placebo (n=40) verilmiştir. Amaçlanan nokta ilaç alınımı sonrası 24 saat içinde AF’nin sinüs ritmine dönüşüm hızı olmuştur. AF konversiyon oranı ile 3 antiaritmik ilacın kullanımı ile ilişkiler çoklu lojistik regresyon analiz ile değerlendirilmiştir. Bulgular: Amaçlanan etki, flekainid kullanan hastaların %87.5’inde, amiyodaron kullanan hastaların %85’inde, propafenon kullanan hastaların 85%’inde, plasebo kullanan hastaların ise %17.5’inde (p

🔖

Cite This Article

KONDILI, A., BALLA, İ., PETRELA, E. (2022). Yeni başlayan atriyal fibrilasyonun ilaçla sinüs ritmine döndürülmesi: Üç antiaritmik ilaçla gerçekleştirilen randomize, plasebo-kontrollü çalışma. Anadolu Kardiyoloji Dergisi, Cilt: 11 - Sayı: 7, 600–606. https://ajindex.com/articles/436627

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001
  2. [CrossRef] 2. Kondili A, Kastrati A, Popa Y. Comparative evaluation of verapamil, flecainide, and propafenone for the acute conversion of atrial fibrillation to sinus rhythm. Wien Klin Wochenschr 1990
  3. Capucci A, Villani GQ, Piepoli MF. Reproducible efficacy of loading oral propafenone in restoring sinus rhythm in patients with paroxysmal atrial fibrillation. Am J Cardiol 2003
  4. [CrossRef] 4. Kondili A, Kastrati A, Balla I, Ndrepepa G. Pharmacological conversion of recent atrial fibrillation, A randomized study of seven antiarrhythmic drugs. Circulation 1995
  5. 92 Suppl: 193. 5. Peuhkurinen K, Niemelä M, Ylitalo A, Linnaluoto M, Lilja M, Juvonen J. Effectiveness of amiodarone as a single oral dose for recent- onset atrial fibrillation. Am J Cardiol 2000
  6. [CrossRef] 6. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010
  7. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al
  8. CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001
  9. [CrossRef] 8. Strasberg B. Intravenous amiodarone for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1991
  10. [CrossRef] 9. Cohen-Solal, Juliard JM, Jaeger P, Farinotti P, Dahan M, Charlier P, et al. Reduction of auricular fibrillation and tachycardia using intravenous flecainide. Arch Mal Coeur Vaiss 1987
  11. Borgeat A, Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986
  12. [CrossRef] 11. Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989
  13. [CrossRef] 12. Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, et al. Effectiveness of loading oral flecainide for converting recentonset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992
  14. [CrossRef] 13. Azpitarte J, Alvarez M, Baún O, García R, Moreno E, Martín F,